| Literature DB >> 33171837 |
Mathilde Fournière1,2, Thomas Latire1,2, Djouhar Souak3,4, Marc G J Feuilloley3, Gilles Bedoux1.
Abstract
Dermatological and cosmetics fields have recently started to focus on the human skin microbiome and microbiota, since the skin microbiota is involved in the health and dysbiosis of the skin ecosystem. Amongst the skin microorganisms, Staphylococcus epidermidis and Cutibacterium acnes, both commensal bacteria, appear as skin microbiota sentinels. These sentinels have a key role in the skin ecosystem since they protect and prevent microbiota disequilibrium by fighting pathogens and participate in skin homeostasis through the production of beneficial bacterial metabolites. These bacteria adapt to changing skin microenvironments and can shift to being opportunistic pathogens, forming biofilms, and thus are involved in common skin dysbiosis, such as acne or atopic dermatitis. The current evaluation methods for cosmetic active ingredient development are discussed targeting these two sentinels with their assets and limits. After identification of these objectives, research of the active cosmetic ingredients and products that maintain and promote these commensal metabolisms, or reduce their pathogenic forms, are now the new challenges of the skincare industry in correlation with the constant development of adapted evaluation methods.Entities:
Keywords: Cutibacterium acnes; Staphylococcus epidermidis; biofilm; cosmetic; skin microbiota
Year: 2020 PMID: 33171837 PMCID: PMC7695133 DOI: 10.3390/microorganisms8111752
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1Topographical distribution of Staphylococcus and Cutibacterium bacteria, adapted from Wilson (2005), Grice et al. (2015) and Kong et al. (2012) [6,17,27].
Figure 2Skin–bacteria interactions in dysbiosis (e.g., acne) and healthy skin: focus on Staphylococcus epidermidis and Cutibacterium acnes, adapted from Claudel et al. (2019) and O’Neill et al. (2018) [44,45].
Assessment of the effect of cosmetic active ingredients on Staphylococcus epidermidis and Cutibacterium acnes (growth, virulence, cytotoxicity and biofilm formation).
| Active Names and Composition |
|
| References | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Growth | Virulence | Cytotoxicity on HaCat Keratinocytes | Biofilm Formation | Growth | Virulence | Cytotoxicity on HaCat Keratinocytes | Biofilm Formation | ||
| BioEcolia® | commensal strain MFP04 | ns | [ | ||||||
| + | ns | + | + | ||||||
| PS291® | commensal strain MFP04 | normal skin strain and/or acneic strains (RT4: (HL045PA1/HM-516) and (RT5: HL043PA2/HM-514) | |||||||
| 0 | 0 | 0 | − | 0 | 0 | 0 | − | ||
| ExpoZen® | + | ns | ns | [ | |||||
| UriageTM Thermal Water (UTW) | commensal strain MFP04 | acneic strains RT4 (HL045PA1/HM-516) and RT5 (HL043PA2/HM-514) | [ | ||||||
| − | ns | + | + | − | 0 | 0 | − | ||
| Viniderm® | commensal strain MFP04 | ns | [ | ||||||
| + | ns | 0 | − | ||||||
| MPA-RegulTM | ns | acneic strains RT4 and RT5 | [ | ||||||
| 0 | 0 | 0 | − | ||||||
| Myrtacine® | strain CIP 53117T | [ | |||||||
| − | ns | ns | − | ||||||
| BGM Complex | strain CIP A 179 | [ | |||||||
| − | ns | ||||||||
| ACNILYS® | − | ns | [ | ||||||
| DIOLÉNYL® | strain ATCC6919 | [ | |||||||
| − | ns | ||||||||
ns: not studied; 0: no effect; +: increased effect; −: decreased effect; idd: inhibition dose-dependent.